JP6993402B2 - 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 - Google Patents

抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 Download PDF

Info

Publication number
JP6993402B2
JP6993402B2 JP2019505220A JP2019505220A JP6993402B2 JP 6993402 B2 JP6993402 B2 JP 6993402B2 JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019505220 A JP2019505220 A JP 2019505220A JP 6993402 B2 JP6993402 B2 JP 6993402B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019505220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527555A5 (enExample
JP2019527555A (ja
Inventor
トラン、エリック
ルー、ヨン－チェン
パセット、アンナ
エフ． ロビンズ、ポール
エイ． ローゼンバーグ、スティーヴン
チェン、ジリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2019527555A publication Critical patent/JP2019527555A/ja
Publication of JP2019527555A5 publication Critical patent/JP2019527555A5/ja
Priority to JP2021199878A priority Critical patent/JP7413338B2/ja
Application granted granted Critical
Publication of JP6993402B2 publication Critical patent/JP6993402B2/ja
Priority to JP2023221526A priority patent/JP7649370B2/ja
Priority to JP2025036871A priority patent/JP2025090690A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
JP2019505220A 2016-08-02 2017-07-31 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 Active JP6993402B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021199878A JP7413338B2 (ja) 2016-08-02 2021-12-09 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2023221526A JP7649370B2 (ja) 2016-08-02 2023-12-27 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2025036871A JP2025090690A (ja) 2016-08-02 2025-03-07 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02
US62/369,883 2016-08-02
PCT/US2017/044615 WO2018026691A1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021199878A Division JP7413338B2 (ja) 2016-08-02 2021-12-09 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2019527555A JP2019527555A (ja) 2019-10-03
JP2019527555A5 JP2019527555A5 (enExample) 2020-09-10
JP6993402B2 true JP6993402B2 (ja) 2022-02-03

Family

ID=59564253

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019505220A Active JP6993402B2 (ja) 2016-08-02 2017-07-31 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2021199878A Active JP7413338B2 (ja) 2016-08-02 2021-12-09 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2023221526A Active JP7649370B2 (ja) 2016-08-02 2023-12-27 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2025036871A Pending JP2025090690A (ja) 2016-08-02 2025-03-07 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021199878A Active JP7413338B2 (ja) 2016-08-02 2021-12-09 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2023221526A Active JP7649370B2 (ja) 2016-08-02 2023-12-27 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
JP2025036871A Pending JP2025090690A (ja) 2016-08-02 2025-03-07 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体

Country Status (20)

Country Link
US (6) US10611816B2 (enExample)
EP (2) EP3494133B1 (enExample)
JP (4) JP6993402B2 (enExample)
KR (1) KR102527052B1 (enExample)
CN (2) CN118063591A (enExample)
AU (3) AU2017306038B2 (enExample)
CY (1) CY1125601T1 (enExample)
DK (1) DK3494133T3 (enExample)
ES (1) ES2928051T3 (enExample)
HR (1) HRP20221183T1 (enExample)
HU (1) HUE060121T2 (enExample)
IL (2) IL301894B2 (enExample)
LT (1) LT3494133T (enExample)
PL (1) PL3494133T3 (enExample)
PT (1) PT3494133T (enExample)
RS (1) RS63615B1 (enExample)
SG (2) SG11201900654QA (enExample)
SI (1) SI3494133T1 (enExample)
SM (1) SMT202200379T1 (enExample)
WO (1) WO2018026691A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900654QA (en) * 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2018335274B2 (en) 2017-09-20 2025-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted T cell receptors against mutated RAS
US12227554B2 (en) 2017-10-05 2025-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2613715B (en) 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
JP7857860B2 (ja) * 2019-11-05 2026-05-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｌａ拘束性ｈｏｒｍａｄ１ ｔ細胞受容体およびその使用
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
EP4086281A4 (en) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION
CA3168015A1 (en) * 2020-02-12 2021-08-19 Noam LEVIN Hla class i-restricted t cell receptors against ras with g12d mutation
MX2022009825A (es) * 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
US20230159614A1 (en) * 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
EP4159768A4 (en) * 2020-05-25 2024-11-20 Bristar Immunotech Limited Enhanced synthetic t-cell receptor and antigen receptor
CA3185241A1 (en) 2020-07-13 2022-01-20 Noam LEVIN Hla class ii?restricted drb t cell receptors against ras with g12d mutation
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
JP7829242B2 (ja) * 2020-11-20 2026-03-13 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
EP4251177A4 (en) * 2020-11-25 2025-01-08 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
JP2026501145A (ja) * 2022-12-13 2026-01-14 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025259799A2 (en) * 2024-06-12 2025-12-18 Biontech Us Inc. T cell receptor compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541332A (ja) 2010-09-20 2013-11-14 ビオエンテッヒ・アクチェンゲゼルシャフト 抗原特異的ｔ細胞受容体およびｔ細胞エピトープ
JP2014528714A (ja) 2011-09-15 2014-10-30 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
WO2015022520A1 (en) 2013-08-12 2015-02-19 Immunocore Limited T cell receptors
JP2018535647A (ja) 2015-09-15 2018-12-06 アメリカ合衆国 Ｈｌａ−ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20140137274A1 (en) * 2011-11-30 2014-05-15 Lsip, Llc Induced malignant stem cells
AU2014276440A1 (en) * 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
SG10201913978RA (en) 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
SG11201900654QA (en) * 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541332A (ja) 2010-09-20 2013-11-14 ビオエンテッヒ・アクチェンゲゼルシャフト 抗原特異的ｔ細胞受容体およびｔ細胞エピトープ
JP2014528714A (ja) 2011-09-15 2014-10-30 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
WO2015022520A1 (en) 2013-08-12 2015-02-19 Immunocore Limited T cell receptors
JP2018535647A (ja) 2015-09-15 2018-12-06 アメリカ合衆国 Ｈｌａ−ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS，2015年01月20日，Vol.112, No.3，pp.779-784

Also Published As

Publication number Publication date
US20200247869A1 (en) 2020-08-06
SG10201913959WA (en) 2020-03-30
EP4159751A1 (en) 2023-04-05
JP2025090690A (ja) 2025-06-17
US11208456B2 (en) 2021-12-28
WO2018026691A1 (en) 2018-02-08
EP3494133A1 (en) 2019-06-12
SI3494133T1 (sl) 2022-11-30
EP3494133B1 (en) 2022-07-06
IL301894B1 (en) 2024-10-01
IL264425B1 (en) 2023-05-01
JP2022050400A (ja) 2022-03-30
US11840561B2 (en) 2023-12-12
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
HRP20221183T1 (hr) 2022-12-09
IL301894A (en) 2023-06-01
IL264425B2 (en) 2023-09-01
KR102527052B1 (ko) 2023-04-27
EP4159751B1 (en) 2026-07-08
AU2023233125B2 (en) 2025-10-16
US20210300988A1 (en) 2021-09-30
US20220089677A1 (en) 2022-03-24
US20190177395A1 (en) 2019-06-13
JP7413338B2 (ja) 2024-01-15
PT3494133T (pt) 2022-09-28
JP2024045139A (ja) 2024-04-02
US20250340611A1 (en) 2025-11-06
AU2023233125A1 (en) 2023-10-12
IL301894B2 (en) 2025-02-01
KR20190064566A (ko) 2019-06-10
US10611816B2 (en) 2020-04-07
IL264425A (enExample) 2019-03-31
HUE060121T2 (hu) 2023-01-28
US12391742B2 (en) 2025-08-19
CN109790211B (zh) 2024-03-26
AU2017306038A1 (en) 2019-02-14
AU2026200276A1 (en) 2026-02-19
CN109790211A (zh) 2019-05-21
RS63615B1 (sr) 2022-10-31
CY1125601T1 (el) 2026-02-25
DK3494133T3 (da) 2022-09-19
CN118063591A (zh) 2024-05-24
US20240209059A1 (en) 2024-06-27
US11897933B2 (en) 2024-02-13
JP7649370B2 (ja) 2025-03-19
SMT202200379T1 (it) 2022-11-18
PL3494133T3 (pl) 2022-11-21
JP2019527555A (ja) 2019-10-03
SG11201900654QA (en) 2019-02-27
LT3494133T (lt) 2022-12-12
ES2928051T3 (es) 2022-11-15

Similar Documents

Publication Publication Date Title
JP7649370B2 (ja) 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
EP3901169B1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
JP2023175703A (ja) 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP2021104044A (ja) 抗突然変異ｋｒａｓ ｔ細胞受容体
JP2023534241A (ja) Ｇ１２ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体
CA3032870C (en) Anti-kras-g12d t cell receptors
HK40009637A (en) Anti-kras-g12d t cell receptors
HK40009637B (en) Anti-kras-g12d t cell receptors
HK40008470B (en) Anti-kras-g12d t cell receptors
HK40008470A (en) Anti-kras-g12d t cell receptors
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190507

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211209

R150 Certificate of patent or registration of utility model

Ref document number: 6993402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250